Ir para o conteúdo principal

AustraliaÚltimas notícias

Grafa
Health

FDA acknowledges pain-reduction benefits of Mesoblast's rexlemestrocel-L

Mesoblast (ASX:MSB), a leader in allogeneic cellular medicines, reported that the US Food & Drug Administration has acknowledged that data from the company's first Phase 3 trial of rexlemestrocel-L for chronic discogenic low back pain favour the therapy in reducing pain intensity.

Leia mais: FDA acknowledges pain-reduction benefits of Mesoblast's rexlemestrocel-L